CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 164 filers reported holding CLOVIS ONCOLOGY INC in Q4 2020. The put-call ratio across all filers is 1.33 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $102,000 | -8.1% | 17,500 | +6.1% | 0.01% | -16.7% |
| Q2 2020 | $111,000 | 0.0% | 16,500 | -5.7% | 0.01% | -14.3% |
| Q1 2020 | $111,000 | -35.8% | 17,500 | +5.6% | 0.01% | -17.6% |
| Q4 2019 | $173,000 | +332.5% | 16,578 | +61.7% | 0.02% | +325.0% |
| Q3 2019 | $40,000 | -70.6% | 10,250 | +12.3% | 0.00% | -73.3% |
| Q2 2019 | $136,000 | -32.3% | 9,125 | +12.3% | 0.02% | -34.8% |
| Q1 2019 | $201,000 | +1446.2% | 8,125 | +983.3% | 0.02% | +1050.0% |
| Q4 2018 | $13,000 | -99.8% | 750 | +50.0% | 0.00% | +100.0% |
| Q3 2018 | $7,349,000 | +14032.7% | 500 | -56.5% | 0.00% | -83.3% |
| Q2 2018 | $52,000 | +73.3% | 1,150 | +100.0% | 0.01% | +50.0% |
| Q1 2018 | $30,000 | +76.5% | 575 | +130.0% | 0.00% | +100.0% |
| Q4 2017 | $17,000 | -84.7% | 250 | -81.5% | 0.00% | -86.7% |
| Q3 2017 | $111,000 | – | 1,350 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,997,826 | $10,834,000 | 0.69% |
| Ikarian Capital, LLC | 1,112,669 | $3,016,000 | 0.45% |
| Versant Venture Management, LLC | 101,855 | $276,000 | 0.15% |
| Virtus ETF Advisers LLC | 60,836 | $165,000 | 0.06% |
| EMFO, LLC | 21,500 | $58,000 | 0.05% |
| QVT Financial LP | 505,000 | $1,369,000 | 0.05% |
| QVT Financial LP | 505,000 | $1,369,000 | 0.05% |
| PINNACLE ASSOCIATES LTD | 706,336 | $1,914,000 | 0.03% |
| XTX Topco Ltd | 20,920 | $57,000 | 0.03% |
| State of Wyoming | 25,419 | $69,000 | 0.03% |